Legend Biotech (LEGN) Non-Current Assets (2019 - 2026)
Legend Biotech's (LEGN) quarterly Non-Current Assets came in at $514.0 million in Q1 2026, up 29.52% YoY from $396.9 million in Q1 2025, and up 5.63% on a QoQ basis from $486.6 million in Q4 2025.
Legend Biotech (LEGN) Non-Current Assets (2019 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 8 years of Non-Current Assets data on file, last reported at $514.0 million in Q1 2026.
- Quarterly Non-Current Assets rose 29.52% year-over-year to $514.0 million in Q1 2026, while the trailing twelve-month figure through Dec 2025 was $486.6 million (up 25.96% YoY) and the FY2025 annual result came in at $486.6 million, up 25.96% from the prior year.
- Non-Current Assets rose to $514.0 million in Q1 2026, from $486.6 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $514.0 million in Q1 2026 to a low of $179.8 million in Q1 2022.
- A 5-year average of $368.0 million and a median of $373.4 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets jumped 128148.17% — and 2025, when it advanced 9.84%.
- Tracing LEGN's Non-Current Assets over 5 years: stood at $231.8 million in 2022, then surged by 51.31% to $350.8 million in 2023, then gained by 10.12% to $386.3 million in 2024, then climbed by 25.96% to $486.6 million in 2025, then gained by 5.63% to $514.0 million in 2026.
- The last three Non-Current Assets figures came in at $514.0 million (Q1 2026), $486.6 million (Q4 2025), and $470.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn | 523.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 523.50 Mn |
| Mar 31, 2026 | 514.00 Mn |
| Dec 31, 2025 | 486.60 Mn |
| Sep 30, 2025 | 470.94 Mn |
| Jun 30, 2025 | 440.04 Mn |
| Mar 31, 2025 | 396.86 Mn |
| Dec 31, 2024 | 386.30 Mn |
| Sep 30, 2024 | 385.79 Mn |
| Jun 30, 2024 | 373.35 Mn |
| Mar 31, 2024 | 361.32 Mn |
| Dec 31, 2023 | 350.81 Mn |
| Sep 30, 2023 | 330.54 Mn |
| Jun 30, 2023 | 317.80 Mn |
| Mar 31, 2023 | 293.96 Mn |
| Dec 31, 2022 | 231.84 Mn |
| Mar 31, 2022 | 179.78 Mn |
| Dec 31, 2021 | 169.62 Mn |
| Sep 30, 2021 | 160.40 Mn |
| Jun 30, 2021 | 154.29 Mn |
| Mar 31, 2021 | 140,179.00 |